Sagimet Biosciences Series A (SGMT) vs Shattuck Labs (STTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Shattuck Labs (STTK) has outperformed Sagimet Biosciences Series A (SGMT) over the past year, gaining 171.4% versus a gain of 22.0%. Sagimet Biosciences Series A is the larger company by market cap ($633.2 million vs $599.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SGMT | STTK |
|---|---|---|
| Share price | $8.93 | $5.97 |
| Market cap | $633.21M | $599.17M |
| 1-day change | +0.11% | +5.48% |
| YTD return | +50.68% | +63.56% |
| 1-year return | +22.02% | +171.36% |
| 5-year return | — | -70.72% |
| EPS (TTM) | $-1.27 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.45 | $8.33 |
| 52-week low | $4.50 | $1.70 |
| Distance from 52-week high | -22.00% | -28.33% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +212.54% | +154.94% |
| Average volume | 1.24M | 1.23M |
| Shares outstanding | 70.34M | 100.36M |
| Employees | 16 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STTK has outperformed SGMT by 149.3 percentage points over the past year.
About Sagimet Biosciences Series A
SGMT stock →Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
SGMT vs STTK FAQ
Which is bigger, Sagimet Biosciences Series A or Shattuck Labs?
Sagimet Biosciences Series A (SGMT) is larger, with a market capitalization of $633.21M compared with $599.17M for Shattuck Labs (STTK).
Which stock has performed better over the past year, SGMT or STTK?
STTK returned +171.36% over the past 12 months, compared with +22.02% for SGMT (price return, excluding dividends). Past performance does not predict future results.
Are Sagimet Biosciences Series A and Shattuck Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.